Straits Times Index
3,303.66 +12.96 (+0.39%) S&P 500
5,222.57 -0.11 (-0.00%) Dow
39,452.72 -60.12 (-0.15%) Nasdaq
16,386.34 +45.47 (+0.28%) Bitcoin USD
62,763.36 +1,402.56 (+2.29%) CMC Crypto 200
1,290.38 +30.17 (+2.40%)
NVO Jan 2026 160.000 put
| Previous close | 40.67 |
| Open | 40.67 |
| Bid | 37.70 |
| Ask | 40.05 |
| Strike | 160.00 |
| Expiry date | 2026-01-16 |
| Day's range | 40.67 - 40.67 |
| Contract range | N/A |
| Volume | |
| Open interest | 24 |
GlobeNewswireNovo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. The trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in people aged 12 years or older with haemophilia A with or without inhibitors. The trial achieved its co-primary endp
- Reuters
UPDATE 2-Denmark faces Wegovy shortage due to rising demand
Denmark faces a supply shortage for two doses of Novo Nordisk's Wegovy weight-loss drug in the coming months due to rising demand, the Danish Medicines Agency said on Monday. The hugely popular Wegovy is given by weekly injection and belongs to a class of drugs known as GLP-1 agonists originally developed to treat type 2 diabetes. There will be a shortage of Novo Nordisk's Wegovy Flextouch 1 milligram pen from late May to mid-June, the Danish medicines agency said in a statement.
The Telegraph‘Outrageously’ expensive Ozempic should be cheaper, says Bernie Sanders
Ozempic and Wegovy maker Novo Nordisk should be forced to cut the price of its obesity and diabetes wonder drugs, Bernie Sanders has said, claiming the current costs are “outrageously high”.
